Conference Call with Aditya Birla Real Estate Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Agrochemicals company Sharda croreopchem announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations: Rs 1,828.5 crore in Q4FY25 vs. Rs 1,312.1 crore in Q4FY24 — up 39% Gross Profit: Rs 544.0 crore in Q4FY25 vs. Rs 453.8 crore in Q4FY24 — up 20% Gross Profit Margin: 29.8% in Q4FY25 vs. 34.6% in Q4FY24 — down 480 bps EBITDA: Rs 351.8 crore in Q4FY25 vs. Rs 302.7 crore in Q4FY24 — up 16% EBITDA Margin: 19.2% in Q4FY25 vs. 23.1% in Q4FY24 — down 390 bps PAT: Rs 203.6 crore in Q4FY25 vs. Rs 143.5 crore in Q4FY24 — up 42% FY25 Financial Highlights: Revenue from Operations: Rs 4,319.9 crore in FY25 vs. Rs 3,163 crore in FY24 — up 37% Gross Profit: Rs 1,291.8 crore in FY25 vs. Rs 820.6 crore in FY24 — up 57% Gross Profit Margin: 29.9% in FY25 vs. 25.9% in FY24 — up 400 bps EBITDA: Rs 681.6 crore in FY25 vs. Rs 318.1 crore in FY24 — up 114% EBITDA Margin: 15.8% in FY25 vs. 10.1% in FY24 — up 570 bps PAT: Rs 304.4 crore in FY25 vs. Rs 31.9 crore in FY24 — up 854% Commenting on the Results, Ramprakash Bubna, Chairman and MD, said, “During Q4 FY25, the Company has witnessed a revival in demand with Revenues growing by 39% YoY to Rs 1,829 crore despite facing ongoing global challenges and sustained pricing pressures. This resurgence has translated into a strong operational and financial performance in Q4 FY25, reflecting resilience in our business model and the effectiveness of the initiatives taken. For FY25, Revenues grew by 37% YoY to Rs 4,320 crore. Gross profit margins expanded by 400 basis points to 29.8%, demonstrating our pricing resilience amid global headwinds. EBITDA more than doubled to Rs 682 crore, with EBITDA margins at 15.8%, aligning with our guidance. Agrochemical volumes saw a robust growth of 44% during the year. With raw material prices stabilising, we expect consistency in gross margins going ahead. Our strong pipeline of registrations reflects both our resilience and unwavering commitment to growth, laying a strong foundation for sustained future progress. We are confident on our ongoing plan to increase product registrations in FY26 with capex guidance of Rs 400-450 crore. For FY26, we aim to grow our topline by more than 15% while maintaining healthy EBITDA margins in the range of 15–18%.” Result PDF